Stock Events

MEI Pharma 

$3.35
28
+$0.15+4.57% Wednesday 19:18

Statistics

Day High
-
Day Low
-
52W High
6.91
52W Low
2.81
Volume
6,528
Avg. Volume
20,033
Mkt Cap
21.85M
P/E Ratio
1.1
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

9MayExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q3 2023
Q4 2023
Next
-2.87
0.91
4.68
8.46
Expected EPS
-1.35
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MEIP. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Analyst Ratings

7$Average Price Target
The highest estimate is $7.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

About

Health Technology
Pharmaceuticals: Other
Manufacturing
Pharmaceutical Preparation Manufacturing
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Show more...
CEO
Daniel Gold
Employees
46
Country
US
ISIN
US55279B2025
WKN
000A1KATX

Listings